The sickle cell treatments available before Casgevy focused on symptom management such as reducing the frequency of ...

CRISPR Therapeutics AG ( NASDAQ: CRSP) TD Cowen 45th Annual Healthcare Conference March 3, 2025 10:30 AM ET ...

Biotech companies can skyrocket in a short period because of excellent clinical or regulatory progress. And if we take the ...

The stock, which has tumbled more than 45% over the past year, could climb 87% within the coming 12 months, Wall Street ...

Esther Nkemakolam runs her fingers through kinetic sand and sings a “Moana” song as UPMC Children’s Hospital nurse Taylor ...

In December 2023, through the development efforts of CRISPR Therapeutics and Vertex Pharmaceuticals, their decades-long ...

There are plenty of great investment alternatives in the healthcare sector. You won't need a boatload of money to get started ...

There is huge unmet need for new rare disease therapies, where patients have few or no available options. According to the ...

Casgevy, a gene therapy for sickle cell disease and beta thalassemia developed with Vertex Pharmaceuticals, has had a fairly slow rollout, but its launch seems to be gaining momentum. Fifty ...

In a sense, every investor is a growth investor. Even those who are primarily seeking income enjoy when the stocks they buy ...

While there is plenty of excitement about the new gene editing treatment, Casgevy, some in the sickle-cell community say they have been let down before and worry about being let down again.

Bluebird bio (BLUE) shares continued their downward descent Monday following news that the company plans to be taken private through a deal valued at up to $96M. Read more here.